www.laigobio.com A collaboration for the creation of a company specialized in the development of a new biological approach for the treatment of cancer and neurological disorders. Argobio and the Oncode Institute will support the company's development to Series A financing. Utrecht (Netherlands), and Paris (France), February 08th 2022 - ArgoBio and Oncode Institute have teamed up with Oncode Investigator Madelon Maurice, researcher and group leader at UMC Utrecht, to launch Laigo Bio, a new company in the emerging field of target protein degradation. The company has additionally secured funding from Oncode Bridge Fund and ArgoBio to further develop its proprietary pipeline of targeted immunotherapies SureTACsR. The SureTACsR technology platform is a novel approach in membrane protein degradation, applicable to a broad scope of disease applications. The primary focus lies in the area of oncology, but with parallel programs in neuro-inflammation and neuro degenerative diseases. In contrast to other small molecule approaches, this results in an efficient and sustained degradation of target receptors, potentially resulting in superior efficacy in the clinic than modalities currently being employed by other emerging protein degradation technologies. Initially driven by Madelon Maurice, who will join as the Principal Investigator, Laigo Bio is gearing up for preclinical lead development in the coming months, generating proprietary biologics for a selection of targets to showcase its potential. Laigo Bio receives strong support from seasoned entrepreneurs Neill Moray Mackenzie at ArgoBio and Emil Pot at Oncode, who will prepare the company for a Series A investment round as it aims to initiate its first clinical studies in 2025. Dr. Neill Moray Mackenzie at ArgoBio is a veteran of the IO field and Mr Emil Pot is an IP & business development expert at Oncode with 25 years of experience in life sciences. Chris De Jonghe, Valorization Director of Oncode Institute, said: “SureTACsR is building on the innovative ideas that Dr. Maurice has initially validated with the support of Oncode’s Technology Development Fund. With the foundation of Laigo Bio, another exciting step forward is made towards the translation of Dr. Maurice’s innovations into effective, and tailored therapies for cancer patients. We are thrilled to join forces with ArgoBio in this initial seed round and consider it as a token of great confidence in the potential of this platform technology.” Madelon Maurice of the UMC Utrecht, said:“We are extremely happy that ArgoBio is supporting my long-standing research here at the UMC Utrecht on how to interfere with signalling alterations that drive oncogenesis and bringing a team of experienced scientists and entrepreneurs to help with its translation to the clinic.” Dr. Neill Moray Mackenzie of ArgoBio, said: “This is exactly why we put ArgoBio together last year – to fund these early-stage opportunities. I am especially pleased that Madelon Maurice, a renowned KOL in the field, is leading this novel approach to protein degradation which has great potential to open up a completely new biology in the field of cancer therapy.” Shobhit Dhawan of Oncode Bridge Fund, said: “Targeted protein degradation is an exciting space and has gained validation in clinical studies with many players now entering the field. One key differentiator here is sustained degradation of cell membrane bound proteins with a biologic, which is a very novel approach, and we believe holds a lot of promise in oncology and many neurological indications. We look forward to supporting Madelon, Neill and Emil in their journey at Laigo Bio.”

Argobio successfully facilitated fundraising and syndication process, following its earlier role in creating and pre-seed funding Laigo Bio Financing co-led by Kurma Partners and Curie Capital Laigo Bio is the second of eight Argobio-founded companies to achieve a seed financing to date Paris, France - 04 December 2025. Argobio Studio, the launchplatform for Europe’s best medicinal science, announced today the launch of Laigo Bio, with €11.5 million seed financing from a strong European investor syndicate. The financing was co-ledby Kurma Partners and Curie Capital, and includes Cancer Research Horizons, Angelini Ventures, Eurazeo, the Oncology Bridge Fund at the Oncode Institute, and ROM Utrecht region, in addition to Argobio. Laigo Bio, headquartered in Utrecht, the Netherlands, is pioneering novel and highly differentiated therapies using its proprietary SureTAC™ precision membrane protein degradation platform. The proceeds from the seed financing will be used to advance its oncology and immunology drug candidate pipeline. “We are pleased to take additional seed funding for Laigo Bio which we have supported since its inception. Its differentiated targeted membrane protein degradation platform enables access to disease mechanisms previously viewed as undruggable, holding tremendous potential benefit for human health. This new funding allows us to pivot into immunology, an emerging therapeutic area for TPD,” said Neill Moray Mackenzie, Partner and Entrepreneur in Residence at Argobio, and Chairman of Laigo Bio. “I am thrilled to welcome our new investors. Argobio has been instrumental in the creation and pre-seed funding of Laigo Bio; thanks to their vision and collaborative support, we are now able to advance further our novel approach to developing protein degradation drug candidates,” said Matthew Baker, Chief Executive Officer of Laigo Bio. “Our SureTAC platform is able to stimulate selective degradation of membrane-bound targets, which we believe could lead to more transformative therapies for patients with autoimmune and inflammatory diseases.” “This is our second company launch this year, which highlights the expertise and ability of our team of operational venture builders to rapidly translate transformational science into globally competitive biotech ventures. We now have a portfolio of eight companies that we have founded from the most cutting-edge European science,” added Thierry Laugel, Chairman of the Management Board of Argobio and Managing Partner at Kurma Partners. Another Argobio company, Elkedonia, announced an €11.25 million seed financing in June 2025 to advance discovery of its first-in-class non-hallucinogenic neuroplasticity enhancing antidepressant candidates for treatment-resistant depression. Laigo Bio (www.laigobio.com), an early stage biotech company based in the Netherlands, is the first company to leverage E3 ligase internalization for the selective degradation of membrane-bound targets involved in autoimmune and inflammatory diseases. Its proprietary SureTAC™ platform creates bispecific antibodies that target the optimal pair of E3 ligase and disease-causing target to stimulate ubiquitination and lysosomal degradation of the target protein with a high degree of specificity. Degradation of the target protein achieves deeper inhibition of disease pathways, while sparing the desirable functions of the target cell. Argobio Studio (www.argobiostudio.com) is thelaunch platformfor Europe’s best science. We turn cutting-edge science into globally competitive European companies pioneering breakthrough therapeutics for patients around the world. As operational venture builders, we reduce execution risk by co-founding, investing, and embedding our experienced, collaborative team, accelerating development with industrial rigor and speed toward value-creating milestones.